Maxim initiated coverage of Nuvectis Pharma (NVCT) with a Buy rating and $17 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCT:
- Nuvectis Pharma initiated with a Buy at Laidlaw
- Nuvectis announces new publication of research study on NXP900, osimertinib
- Nuvectis Pharma Reports 2024 Financial Results and Progress
- Nuvectis Pharma initiated with a Buy at Lucid Capital
- Optimistic Buy Rating for Nuvectis Pharma Driven by Promising Oncology Pipeline and Strong Financial Position